What is BioSpherix?
BioSpherix operates as a specialized innovator in the field of advanced cell and tissue culture technology. By pioneering the concept of Cytocentric environments, the company addresses the critical need for physiological accuracy in laboratory settings. Their core product portfolio, anchored by the modular Xvivo System and precision gas controllers, provides researchers with the tools necessary to maintain optimal cell viability. By integrating patented self-sanitizing technology into their hardware, BioSpherix effectively mitigates contamination risks, thereby enhancing the reproducibility and reliability of data within the biomedical and pharmaceutical research landscapes. The company's commitment to economical, customizable solutions positions it as a vital infrastructure provider for modern life sciences.
How much funding has BioSpherix raised?
BioSpherix has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in BioSpherix
PPP
Public-Private Partnership
What's next for BioSpherix?
Following this major strategic investment, BioSpherix is well-positioned to accelerate its market penetration and expand its technological footprint. The infusion of capital will likely be directed toward scaling the production of the Xvivo System and further refining its automated cell care solutions. As the demand for high-fidelity cell culture environments grows in tandem with advancements in regenerative medicine and drug discovery, BioSpherix is poised to leverage its late-stage funding to capture additional market share. Strategic priorities will likely include enhancing global distribution channels and investing in R&D to maintain its competitive edge in Cytocentric technology, ensuring the firm remains at the forefront of laboratory automation and cell research standards.
See full BioSpherix company page
